Searched for: author:"Princen, H.M.G."
(1 - 20 of 119)

Pages

document
Schlunk, F. (author), Fisher, P. (author), Princen, H.M.G. (author), Rex, A. (author), Prinz, V. (author), Foddis, M. (author), Lütjohann, D. (author), Laufs, U. (author), Endres, M. (author)
Monoclonal anti-proprotein convertase subtilisin/kexin type 9 (PSCK9) neutralizing antibodies effectively lower plasma cholesterol levels and decrease cardiovascular events but also raised some concern that cognitive function could worsen as a side effect. Here, we performed experiments in mice to characterize the effect of anti-PCSK9 antibodies...
article 2021
document
Gopaul, V.S. (author), Pieterman, E.J. (author), Princen, H.M.G. (author), Bergenholm, L. (author), Lundborg, E. (author), Cavallin, A. (author), Johansson, M.J. (author), Hawthorne, G. (author), Björkbom, A. (author), Hammarberg, M. (author), Li, X. (author), Jarke, A. (author), Bright, J. (author), Svensson, L. (author), Jansson-Löfmark, R. (author), Abrahamsson, B. (author), Agrawal, R. (author), 1 Hurt-Camejo, E. (author)
We investigated the effects of mineral oil on statin pharmacokinetics and inflammatory markers in animal models. A new synthesis strategy produced regioisomers that facilitated the characterization of the main metabolite (M1) of atorvastatin, a lipophilic statin, in C57BL/6NCrl mice. The chemical structure of M1 in mice was confirmed as ortho...
article 2021
document
van den Hoek, A.M. (author), Verschuren, L. (author), Caspers, M.P.M. (author), Worms, N. (author), Alonso, C. (author), Menke, A.L. (author), Princen, H.M.G. (author)
Non-alcoholic steatohepatitis (NASH) is the most rapidly growing liver disease that is nevertheless without approved pharmacological treatment. Despite great effort in developing novel NASH therapeutics, many have failed in clinical trials. This has raised questions on the adequacy of preclinical models. Elafibranor is one of the drugs currently...
article 2021
document
van Keulen, D. (author), van Koeverden, I.D. (author), Boltjes, A. (author), Princen, H.M.G. (author), van Gool, A.J. (author), Asselbergs, F.W. (author), Tempel, D. (author), Pasterkamp, G. (author), van der Laan, S.W. (author)
Background and Aims: Oncostatin M (OSM) signaling is implicated in atherosclerosis, however the mechanism remains unclear. We investigated the impact of common genetic variants in OSM and its receptors, OSMR and LIFR, on overall plaque vulnerability, plaque phenotype, intraplaque OSMR and LIFR expression, coronary artery calcification burden and...
article 2021
document
van Gemert, Y. (author), Kozijn, A.E. (author), Pouwer, M.G. (author), Kruisbergen, N.N.L. (author), van den Bosch, M.H.J. (author), Blom, A.B. (author), Pieterman, E.J. (author), Weinans, H. (author), Stoop, R. (author), Princen, H.M.G. (author), van Lent, P.L.E.M. (author)
Objective: High systemic cholesterol levels have been associated with osteoarthritis (OA) development. Therefore, cholesterol lowering by statins has been suggested as a potential treatment for OA. We investigated whether therapeutic high-intensive cholesterol-lowering attenuated OA development in dyslipidemic APOE*3Leiden.CETP mice. Methods:...
article 2021
document
Fragki, S.S. (author), Dirven, H. (author), Fletcher, T. (author), Grasl-Kraupp, B. (author), Guetzkow, K.B. (author), Hoogenboom, R. (author), Kersten, S. (author), Lindeman, B. (author), Louisse, J. (author), Peijnenburg, A. (author), Aldert H., (author), Piersma, A.H. (author), Princen, H.M.G. (author), Uhl, M. (author), Westerhout, J. (author), Zeilmaker, M.J. (author), Luijten, M. (author)
Associations between per- and polyfluoroalkyl substances (PFASs) and increased blood lipids have been repeatedly observed in humans, but a causal relation has been debated. Rodent studies show reverse effects, i.e. decreased blood cholesterol and triglycerides, occurring however at PFAS serum levels at least 100-fold higher than those in humans....
article 2021
document
van den Hoek, A.M. (author), Pieterman, E.J. (author), van der Hoorn, J.W. (author), Iruarrizaga-Lejarreta, M. (author), Alonso, C. (author), Verschuren, L. (author), Skjæret, T. (author), Princen, H.M.G. (author), Fraser, D.A. (author)
Icosabutate is a structurally engineered eicosapentaenoic acid derivative under development for nonalcoholic steatohepatitis (NASH). In this study, we investigated the absorption and distribution properties of icosabutate in relation to liver targeting and used rodents to evaluate the effects of icosabutate on glucose metabolism, insulin...
article 2020
document
Stokman, G. (author), van den Hoek, A.M. (author), Denker Thorbekk, D. (author), Pieterman, E.J. (author), Skovgård Veidal, S. (author), Basta, B. (author), Iruarrizaga-Lejarreta, M. (author), van der Hoorn, J.W. (author), Verschuren, L. (author), Berbée, J.F.P. (author), Rensen, P.C.N. (author), Skjæret, T. (author), Alonso, C. (author), Feigh, M. (author), Kastelein, J.J.P. (author), Friedman, S.L. (author), Princen, H.M.G. (author), Fraser, D.A. (author)
article 2020
document
Schlunk, F. (author), Fisher, P. (author), Princen, H.M.G. (author), Rex, A. (author), Prinz, V. (author), Foddis, M. (author), Lütjohann, D. (author), Laufs, U. (author), Endres, M. (author)
Anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies lower low-density lipoprotein cholesterol levels and significantly reduce cardiovascular end points.1 Safety concerns were raised as ultra-low levels of low-density lipoprotein cholesterol can be achieved. Low cholesterol levels are associated with an increased rate of...
article 2020
document
Härdtner, C. (author), Kornemann, J. (author), Krebs, K. (author), Ehlert, C.A. (author), Jander, A. (author), Zou, J. (author), Christopher, (author), Starz, C. (author), Rauterberg, S. (author), Sharipova, D. (author), Dufner, B. (author), Hoppe, N. (author), · Dederichs, T-S. (author), Willecke, F. (author), Stachon, p. (author), Heidt, T. (author), Wolf, D. (author), von zur Mühlen, C. (author), Madl, J. (author), Kohl, P. (author), Kaeser, R. (author), Boettler, T. (author), Pieterman, E.J. (author), Princen, H.M.G. (author), Ho‑Tin‑Noé, B. (author), Swirski, F.K. (author), Robbins, C.S. (author), Bode, C. (author), Zirlik, A. (author), Hilgendorf, I. (author)
Statins induce plaque regression characterized by reduced macrophage content in humans, but the underlying mechanisms remain speculative. Studying the translational APOE*3-Leiden.CETP mouse model with a humanized lipoprotein metabolism, we find that systemic cholesterol lowering by oral atorvastatin or dietary restriction inhibits monocyte...
article 2020
document
Bar, A. (author), Kieronska-Rudek, A. (author), Proniewski, B. (author), Suraj-Prażmowska, J. (author), Czamara, K. (author), Marczyk, B. (author), Matyjaszczyk-Gwarda, K. (author), Jasztal, A. (author), Kuś, E. (author), Majka, Z. (author), Kaczor, A. (author), Kurpińska, A. (author), Walczak, M. (author), Pieterman, E.J. (author), Princen, H.M.G. (author), Chlopicki, S. (author)
Background Long-term feeding with a high-fat diet (HFD) induces endothelial dysfunction in mice, but early HFD-induced effects on endothelium have not been well characterized. Methods and Results Using an magnetic resonance imaging-based methodology that allows characterization of endothelial function in vivo, we demonstrated that short-term (2...
article 2020
document
Pouwer, M.G. (author), Heinonen, S.E. (author), Behrendt, M. (author), Andréasson, A.M. (author), van Koppen, A. (author), Menke, A.L. (author), Pieterman, E.J. (author), van den Hoek, A.M. (author), Jukema, J.W. (author), Leighton, B. (author), Jonsson-Rylander, A.M. (author), Princen, H.M.G. (author)
Background. There is a lack of predictive preclinical animal models combining atherosclerosis and type 2 diabetes. APOE*3-Leiden (E3L) mice are a well-established model for diet-induced hyperlipidemia and atherosclerosis, and glucokinase+/− (GK+/−) mice are a translatable disease model for glucose control in type 2 diabetes. The respective mice...
article 2019
document
Schuster, S. (author), Rubil, S. (author), Endres, M. (author), Princen, H.M.G. (author), Boeckel, J.N. (author), Winter, K. (author), Werner, C. (author), Laufs, U. (author)
LDL-cholesterol (LDL-C) is a causal pathogenic factor in atherosclerosis. Monoclonal anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) neutralizing antibodies are novel potent LDL-lowering drugs which reduce cardiovascular events. To characterize their effect on atherogenesis, APOE*3Leiden.CETP mice were fed a high cholesterol/high fat...
article 2019
document
van Keulen, D. (author), Pouwer, M.G. (author), Emilsson, V. (author), Matic, L.P. (author), Pieterman, E.J. (author), Hedin, U. (author), Gudnason, V. (author), Jennings, L.L. (author), Holmstrøm, K. (author), Nielsen, B.S. (author), Pasterkamp, G. (author), Lindeman, J.H.N. (author), van Gool, A.J. (author), Sollewijn Gelpke, M.D. (author), Princen, H.M.G. (author), Tempel, D. (author)
OBJECTIVE: Previous studies indicate a role for Oncostatin M (OSM) in atherosclerosis and other chronic inflammatory diseases for which inhibitory antibodies are in development. However, to date no intervention studies with OSM have been performed, and its relation to coronary heart disease (CHD) has not been studied. APPROACH AND RESULTS: Gene...
article 2019
document
Pouwer, M.G. (author), Pieterman, E.J. (author), Worms, N. (author), Keijzer, N. (author), Jukema, J.W. (author), Gromada, J. (author), Gusarova, V. (author), Princen, H.M.G. (author)
Atherosclerosis-related cardiovascular disease causes nearly 20 million deaths annually. Most patients are treated after plaques develop, so therapies must regress existing lesions. Current therapies reduce plaque volume, but targeting all apoB-containing lipoproteins with intensive combinations that include alirocumab or evinacumab-monoclonal...
article 2019
document
Pouwer, M.G. (author), Pieterman, E.J. (author), Chang, S.C. (author), Olsen, G.W. (author), Verschuren, L. (author), Jukema, J.W. (author), Princen, H.M.G. (author)
Epidemiological studies have reported positive associations between serum perfluorooctanoic acid (PFOA) and total and non-high-density lipoprotein cholesterol (non-HDL-C) although the magnitude of effect of PFOA on cholesterol lacks consistency. The objectives of this study were to evaluate the effect of PFOA on plasma cholesterol and...
article 2019
document
Pouwer, M.G. (author), Pieterman, E.J. (author), Verschuren, L. (author), Caspers, M.P.M. (author), Kluft, C. (author), Garcia, R.A. (author), Aman, J. (author), Jukema, J.W. (author), Princen, H.M.G. (author)
Treatment with the second and third generation BCR-ABL1 tyrosine kinase inhibitors (TKIs) increases cardiovascular risk in chronic myeloid leukemia (CML) patients. We investigated the vascular adverse effects of three generations of TKIs in a translational model for atherosclerosis, the APOE*3Leiden.CETP mouse. Mice were treated for sixteen...
article 2018
document
Kozijn, A.E. (author), Gierman, L.M. (author), van der Ham, F. (author), Mulder, P. (author), Morrison, M.C. (author), Kühnast, S. (author), van der Heijden, R.A. (author), Stavro, P.M. (author), van Koppen, A. (author), Pieterman, E.J. (author), van den Hoek, A.M. (author), Kleemann, R. (author), Princen, H.M.G. (author), Mastbergen, S.C. (author), Lafeber, F.P.J.G. (author), Zuurmond, A.M. (author), Bobeldijk, I. (author), Weinans, H. (author), Stoop, R. (author)
Objective. Human cohort studies have demonstrated a role for systemic metabolic dysfunction in osteoarthritis (OA) pathogenesis in obese patients. To explore the mechanisms underlying this metabolic phenotype of OA, we examined cartilage degradation in the knees of mice from different genetic backgrounds in which a metabolic phenotype was...
article 2018
document
Tsikas, D. (author), Hanff, E. (author), Bollenbach, A. (author), Kruger, H. (author), Pham, V.V. (author), Chobanyan-Jürgens, K. (author), Wedekind, D. (author), Arndt, T. (author), Jörns, A. (author), Berbée, J.F.P. (author), Princen, H.M.G. (author), Lücke, T. (author), Mariotti, F. (author), Huneau, J.F. (author), Ückert, S. (author), Frölich, J.C. (author), Lenzen, S. (author)
We recently found that renal carbonic anhydrase (CA) is involved in the reabsorption of inorganic nitrite (NO2−), an abundant reservoir of nitric oxide (NO) in tissues and cells. Impaired NO synthesis in the endothelium and decreased NO bioavailability in the circulation are considered major contributors to the development and progression of...
article 2018
document
van Keulen, D. (author), Pouwer, M.G. (author), Pasterkamp, G. (author), van Gool, A.J. (author), Sollewijn Gelpke, M.D. (author), Princen, H.M.G. (author), Tempel, D. (author)
Aims Endothelial activation is involved in many chronic inflammatory diseases, such as atherosclerosis, and is often initiated by cytokines. Oncostatin M (OSM) is a relatively unknown cytokine that has been suggested to play a role in both endothelial activation and atherosclerosis. We comprehensively investigated the effect of OSM on...
article 2018
Searched for: author:"Princen, H.M.G."
(1 - 20 of 119)

Pages